Integral Health Asset Management LLC Purchases New Stake in Esperion Therapeutics, Inc. $ESPR

Integral Health Asset Management LLC purchased a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,500,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,975,000. Integral Health Asset Management LLC owned 0.63% of Esperion Therapeutics as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ESPR. Jones Financial Companies Lllp acquired a new position in Esperion Therapeutics in the first quarter valued at approximately $278,000. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the second quarter valued at $25,000. Geode Capital Management LLC boosted its holdings in shares of Esperion Therapeutics by 3.1% during the second quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock valued at $4,513,000 after acquiring an additional 137,691 shares during the period. Intech Investment Management LLC grew its position in shares of Esperion Therapeutics by 30.4% during the second quarter. Intech Investment Management LLC now owns 123,040 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 28,695 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Esperion Therapeutics by 16.8% during the second quarter. Rhumbline Advisers now owns 275,688 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 39,658 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Key Headlines Impacting Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Citizens Jmp raised its price target on ESPR to $5.00 (from $4.00) and assigned a “market outperform” rating — implying roughly 105% upside vs. the reference $2.44 level, which could attract buyers and trigger short‑covering. Article Title Article Title
• Neutral Sentiment: Street analysts published Q4 forecasts for ESPR; these refreshes create short‑term volatility but are routine ahead of reporting periods — watch actual Q4 results vs. the new consensus for a catalyst. Article Title
• Negative Sentiment: HC Wainwright lowered multi‑year EPS targets materially while maintaining a “Buy” rating: FY2026 cut to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). The firm also models small quarterly losses (Q1 -$0.08, Q2 -$0.05, Q3 -$0.04) before the projected recovery — the revisions reduce future earnings power embedded in current valuations and likely weigh on the stock. Article Title

Analyst Ratings Changes

A number of research firms have recently weighed in on ESPR. Needham & Company LLC lifted their price target on Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Citizens Jmp upped their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Friday. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating on shares of Esperion Therapeutics in a report on Tuesday. Finally, Piper Sandler began coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Esperion Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.60.

Esperion Therapeutics Stock Down 1.2%

Shares of Esperion Therapeutics stock opened at $2.44 on Friday. Esperion Therapeutics, Inc. has a 12-month low of $0.69 and a 12-month high of $4.18. The firm has a market capitalization of $626.62 million, a PE ratio of -14.35, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11. The stock’s fifty day moving average is $3.28 and its 200-day moving average is $3.14.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million during the quarter, compared to analysts’ expectations of $165.12 million. Analysts expect that Esperion Therapeutics, Inc. will post -0.29 EPS for the current year.

Insider Activity

In other news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the completion of the sale, the chief financial officer owned 467,525 shares in the company, valued at $1,715,816.75. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 15,543 shares of company stock valued at $55,709 in the last ninety days. 1.70% of the stock is owned by corporate insiders.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.